Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Angelo Sambunaris"'
Publikováno v:
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 48(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b9824ed7500dee2220836ae7d2d3739
https://pubmed.ncbi.nlm.nih.gov/36380222
https://pubmed.ncbi.nlm.nih.gov/36380222
Publikováno v:
International Clinical Psychopharmacology
Supplemental Digital Content is available in the text.
The objective of this post-hoc analysis was to investigate the relationship between motivation/energy and functional impairment in patients with major depressive disorder (MDD). Data were ta
The objective of this post-hoc analysis was to investigate the relationship between motivation/energy and functional impairment in patients with major depressive disorder (MDD). Data were ta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd1a3bf42a625056de6b600d45a64fd6
https://doi.org/10.1097/yic.0000000000000138
https://doi.org/10.1097/yic.0000000000000138
Autor:
Angelo Sambunaris, Suresh Durgam, Xiongwen Tang, Giovanna Forero, Carl Gommoll, Maju Mathews, Rene Nunez
Publikováno v:
International Clinical Psychopharmacology
Vilazodone is a selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist that is approved for treatment of major depressive disorder in adults in the USA and Mexico. The efficacy, safety, and tolerability of vilazodone for general
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d4d8790211580585dd46be80230442f
https://doi.org/10.1097/yic.0000000000000096
https://doi.org/10.1097/yic.0000000000000096
Publikováno v:
International Clinical Psychopharmacology
Major depressive disorder (MDD) is characterized by increased rates of impaired function and disability. During antidepressant treatment, functional improvement often lags behind symptomatic resolution, and residual impairment is associated with an i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5514201d414f70747c55c6b7f636e4a
https://doi.org/10.1097/yic.0000000000000033
https://doi.org/10.1097/yic.0000000000000033
Publikováno v:
International Clinical Psychopharmacology
Vilazodone is a potent selective serotonin reuptake inhibitor and serotonin 1A receptor partial agonist approved for the treatment of major depressive disorder in adults. To assess the efficacy of vilazodone across a range of symptoms and severities
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b86bb6aed919f8adaa42100770b98167
https://doi.org/10.1097/yic.0000000000000016
https://doi.org/10.1097/yic.0000000000000016
Autor:
Anjana Bose, Changzheng Chen, Carl Gommoll, William M. Greenberg, Angelo Sambunaris, David V. Sheehan
Publikováno v:
Journal of Clinical Psychopharmacology
Major depressive disorder (MDD) is a leading cause of global disease burden; by 2030, it is projected that it will be only second to human immunodeficiency virus/acquired immunodeficiency syndrome in worldwide burden of disease.1 Some defining sympto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ac0e052c485e56e25b4352f9a2932f2
https://doi.org/10.1097/jcp.0000000000000060
https://doi.org/10.1097/jcp.0000000000000060
Autor:
James Wu, Madhukar H. Trivedi, Angelo Sambunaris, Robert M. Roth, Richard S.E. Keefe, Manisha Madhoo, Colleen Anderson, Robert Lasser
Publikováno v:
Neuropsychopharmacology. 39:1388-1398
Evaluate lisdexamfetamine dimesylate (LDX) augmentation of antidepressant monotherapy for executive dysfunction in partially or fully remitted major depressive disorder (MDD). This randomized, placebo-controlled study (NCT00985725) enrolled 143 adult
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27f6dfda9e632d56498b4cc4d0b2c82a
https://doi.org/10.1038/npp.2013.334
https://doi.org/10.1038/npp.2013.334
Autor:
Philip D. Harvey, Angelo Sambunaris, Carl Gommoll, Roger S. McIntyre, Changzheng Chen, Keith Wesnes
Publikováno v:
International Clinical Psychopharmacology
Performance-based cognitive data were collected using the Cognitive Drug Research System in a study of levomilnacipran extended-release (ER) 40-120 mg/day (NCT01034462) in adults with major depressive disorder. These data were analyzed post-hoc to ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11a8701403c586afea27622e61aa9af6
https://pubmed.ncbi.nlm.nih.gov/27861191
https://pubmed.ncbi.nlm.nih.gov/27861191
Autor:
John H. Greist, Gary D. Tollefson, Craig H. Mallinckrodt, Angelo Sambunaris, Madelaine M. Wohlreich, Apurva Prakash, Andrew A. Nierenberg
Publikováno v:
Current Medical Research and Opinion. 23:401-416
The goal of a non-inferiority study is to test whether a new treatment has at least as much efficacy as an established treatment. The purpose of this non-inferiority study was to compare the speed of onset of antidepressant efficacy for duloxetine (a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67e3ceb04e4ba2e2268864b6afab9592
https://doi.org/10.1185/030079906x167453
https://doi.org/10.1185/030079906x167453
Publikováno v:
International Review of Psychiatry. 7:41-53
SummaryThis article discusses the relevance of serotonin receptor subtype-mediated animal behavioral pharmacology for applications in patients with psychiatric disorders. We thus review the potential of some selective serotonin ligands for treating a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a9cb7c3b91dde29945797d1d8e249c0
https://doi.org/10.3109/09540269509022974
https://doi.org/10.3109/09540269509022974